READDI Receives $65M Grant from NIH to Establish an Antiviral Drug Discovery (AViDD) Center

The READDI-AViDD Center, one of nine established by the NIH, is an integrated public-private partnership with a renowned, interdisciplinary research team of experts from the Gillings School, UNC School of Medicine and UNC Eshelman School of Pharmacy.

“Investment in antiviral drug discovery through open science is the best way to ensure that the world is prepared for the next pandemic,” said Tim Willson, co-director and professor at the UNC Eshelman School of Pharmacy. “READDI-AC will leverage open science to support the development of antiviral drugs that are affordable and available to all.”  

“At Carolina, we talk about practical applications of our research to improve society and the public good. Faced with the threat of COVID-19, our world-class scientists did not back down,” said Chancellor Kevin M. Guskiewicz. “Their continued pursuit of solutions saved lives, and this recent award recognizes the profound impact of that work. I’m grateful for this funding and the continued support of the North Carolina General Assembly, which enables us to perform cutting-edge research and prepare for whatever might be next on the horizon.”

Read the full article here.